homepage-top-section

Based in Boston of Massachusetts, Akcea Therapeutics is engaged in the development and commercialisation of medicines for the treatment of patients with serious and rare diseases. Under the

Gilead had already secured EUA status for Veklury for the treatment of patients hospitalised due to severe Covid-19. The expanded EUA status was granted based on data from

The EC approval enables to use of BLENREP as monotherapy to treat multiple myeloma in adult patients who have secured at least four prior therapies including one proteasome

As part of the deal, Acadia has purchased all of the outstanding shares of CerSci for $52.5m in the form of its stock. CerSci shareholders are also eligible

Forbius is engaged in the designing and development of advanced biotherapeutics to treat cancer and fibrotic diseases. The company has developed a portfolio of selective and potent inhibitors

Oscar A-Co KK, a company controlled by funds managed by The Blackstone Group and its affiliates, has signed an agreement to acquire Takeda’s wholly-owned subsidiary Takeda Consumer Healthcare

The acquisition of Momenta Pharmaceuticals is expected to help the Janssen Pharmaceutical Companies of Johnson & Johnson to grow its position further in immune-mediated diseases and bring in

In October 2018, the companies first announced their collaboration for the discovery, development and commercialisation of advanced targeted immuno-oncology treatments for cancer. As part of the expanded multi-year

As per terms of the deal, Sanofi will purchase all of the outstanding shares of Principia by paying $100 per share in cash. Principia Biopharma is engaged in